Astrana Health
ASTH
37.14
+0.14
+0.38%
Astrana Health
US · ASTH
#2768 by market cap
Listed 1970
37.14
+0.14
+0.38%
Live - 5344 symbols - heartbeat 483s ago
· 2026-10-07 19:54
After-hours
37.14
0.00%
- Market cap
- 2.07B
- P/E (TTM)i
- 45.29
- P/Bi
- 2.49
- EPSi
- 0.46
- Div yieldi
- 0.00%
- 52W posi
- 57%
Reader sentiment
Are you bullish or bearish on ASTH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.63, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +56.39% YoY
Margins
- Gross margin
- 10.73%
- Operating margin
- 2.47%
- Net margin
- 0.71%
Key ratios & quality
- Enterprise valuei
- 2.69B
- Altman Z-Scorei
- 2.63
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 519.91M | 560.62M | 370.25M | 773.92M | 1.14B | 1.39B | 2.03B | 3.18B |
| Gross profit | 158.78M | 92.81M | 21.71M | 177.77M | 199.48M | 214.96M | 271.39M | 341.53M |
| Selling & admin expenses | 43.35M | 41.48M | 15.59M | 62.08M | 77.67M | 112.60M | 154.11M | 217.26M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 92.23M | 34.41M | 6.09M | 98.18M | 104.27M | 84.61M | 89.35M | 78.53M |
| Pretax profit | 82.63M | 25.84M | 8.87M | 77.75M | 86.62M | 89.84M | 80.82M | 39.61M |
| Tax | 22.36M | 8.17M | 9.18M | 31.69M | 40.88M | 31.99M | 30.89M | 15.53M |
| Net profit | 60.27M | 17.67M | -314.00K | 46.06M | 45.74M | 57.85M | 49.93M | 24.08M |
| Basic EPS | 0 | 0 | -1 | 2 | 1 | 1 | 1 | 0 |
| Diluted EPS | 0.29 | 0.39 | -1.03 | 1.52 | 0.99 | 1.29 | 0.90 | 0.46 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 620.39M | 654.81M | 956.05M | 950.53M | 965.10M | 972.52M |
| Gross profit | 71.33M | 77.97M | 97.19M | 95.04M | 105.74M | 104.02M |
| Selling & admin expenses | 43.90M | 50.73M | 62.39M | 60.25M | 61.74M | 54.15M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 20.58M | 20.34M | 19.21M | 18.40M | 28.53M | 34.32M |
| Pretax profit | 9.60M | 16.83M | 5.67M | 7.51M | 19.71M | 27.21M |
| Tax | 3.38M | 6.61M | 4.59M | 944.00K | 6.58M | 8.76M |
| Net profit | 6.22M | 10.22M | 1.08M | 6.56M | 13.13M | 18.45M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.14 | 0.19 | 0.01 | 0.12 | 0.29 | 0.40 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 172.86M | 329.07M | 338.58M | 404.46M | 428.13M | 461.51M | 638.50M | 863.31M |
| Cash & ST investments | 108.02M | 219.73M | 261.17M | 286.51M | 293.59M | 296.31M | 288.46M | 429.47M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 513.00M | 728.71M | 817.49M | 867.36M | 966.21M | 933.36M | 1.35B | 2.22B |
| Total current liabilities | 72.02M | 105.42M | 114.99M | 114.72M | 148.61M | 218.67M | 365.61M | 615.27M |
| Short-term debt | 142.00K | 12.59M | 14.17M | 3.90M | 4.79M | 24.75M | 14.73M | 55.67M |
| Long-term debt | 13.00M | 232.17M | 230.21M | 182.92M | 203.39M | 258.94M | 425.30M | 990.90M |
| Total liabilities | 106,337,868.00 | 367,653,000.00 | 372,338,000.00 | 356,719,000.00 | 407,666,000.00 | 522,593,000.00 | 840,726,000.00 | 1,660,327,000.00 |
| Total equity | 406.66M | 361.06M | 445.15M | 510.64M | 558.55M | 410.77M | 514.17M | 558.33M |
| Retained earnings | 17.79M | 31.91M | 69.77M | 137.25M | 182.42M | 243.13M | 286.28M | 308.38M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 613.27M | 729.15M | 883.63M | 863.31M | 1.00B | 919.16M |
| Cash & ST investments | 260.91M | 342.12M | 463.45M | 429.47M | 478.38M | 400.79M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.33B | 1.44B | 2.24B | 2.22B | 2.36B | 2.28B |
| Total current liabilities | 361.27M | 459.75M | 629.93M | 615.27M | 745.37M | 747.64M |
| Short-term debt | 17.95M | 17.82M | 55.05M | 55.67M | 55.42M | 62.79M |
| Long-term debt | 403.89M | 401.06M | 1.00B | 990.90M | 979.76M | 882.65M |
| Total liabilities | 813,550,000.00 | 904,404,000.00 | 1,682,462,000.00 | 1,660,327,000.00 | 1,781,371,000.00 | 1,683,501,000.00 |
| Total equity | 517.71M | 537.95M | 554.72M | 558.33M | 577.46M | 598.58M |
| Retained earnings | 292.88M | 302.21M | 302.49M | 308.38M | 322.71M | 342.36M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 25.50M | 13.67M | 46.16M | 70.34M | 82.13M | 68.23M | 52.20M | 114.60M |
| Depreciation & amortization | 19.30M | 18.28M | 18.35M | 17.52M | 17.54M | 17.75M | 27.93M | 45.75M |
| Free cash flow | 24.33M | 12.63M | 45.00M | 51.11M | 59.19M | 39.70M | 44.17M | 104.49M |
| Dividends paid | -17.76M | -61.72M | -51.32M | -31.09M | -14.03M | -62.07M | -4.04M | -7.89M |
| Stock buybacks / issuance | -4.85M | -6.82M | -537.00K | 34.40M | -9.25M | -10.19M | -937.00K | -15.43M |
| Ending cash balance | 107.64M | 104.01M | 193.97M | 233.10M | 288.03M | 294.15M | 289.10M | 434.05M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 16.63M | 90.90M | 9.96M | -2.89M | 68.06M | 32.75M |
| Depreciation & amortization | 6.85M | 6.90M | 15.60M | 16.40M | 15.48M | 15.55M |
| Free cash flow | 13.56M | 89.48M | 7.40M | -5.95M | 64.06M | 28.87M |
| Dividends paid | -5.46M | -778.00K | -96.00K | -1.56M | -104.00K | -95.00K |
| Stock buybacks / issuance | 0 | 0 | -- | -- | -2.91M | 100.00K |
| Ending cash balance | 259.16M | 340.35M | 464.33M | 434.05M | 483.30M | 405.74M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 6.36 | 7.59 | 14.50 | 18.81 | 9.74 | 10.41 | 6.50 | 3.01 |
| ROA %i | 2.16 | 2.27 | 4.90 | 8.85 | 5.40 | 6.40 | 3.77 | 1.26 |
| ROIC %i | 5.73 | 4.97 | 8.17 | 12.23 | 7.48 | 7.21 | 5.15 | 2.99 |
| 5-year avg ROE %i | -- | -- | -- | 11.27 | 6.33 | 7.16 | 6.94 | 9.37 |
| EBIT margin %i | 16.00 | 5.45 | 27.35 | 10.74 | 8.26 | 7.64 | 5.60 | 2.81 |
| FCF / sales %i | 4.68 | 2.25 | 6.55 | 6.60 | 5.17 | 2.86 | 2.17 | 3.28 |
| Current ratioi | 2.40 | 3.12 | 2.94 | 3.53 | 2.88 | 2.11 | 1.75 | 1.40 |
| Quick ratioi | 2.30 | 3.02 | 2.80 | 3.36 | 2.78 | 2.03 | 1.68 | 1.36 |
| Debt / assetsi | 2.66 | 35.21 | 31.87 | 23.17 | 23.74 | 34.39 | 34.74 | 48.59 |
| LT debt / equityi | 7.49 | 127.36 | 74.48 | 43.98 | 41.39 | 48.23 | 63.97 | 131.20 |
| Interest coveragei | 148.41 | 6.46 | 19.78 | 15.41 | 11.94 | 6.58 | 3.44 | 1.79 |
| Revenue CAGR (3Y) %i | 145.09 | 128.76 | 1.28 | 14.18 | 26.85 | 55.30 | 38.01 | 40.62 |
| Net income CAGR (3Y) %i | -- | -- | -- | 85.29 | 47.36 | -- | -14.45 | -20.75 |
| FCF CAGR (3Y) %i | -- | -- | -3.29 | 28.08 | 67.34 | -4.09 | -4.75 | 20.86 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 5.00 | 3.50 | 1.29 | 3.01 | 3.91 | 5.08 |
| ROA %i | 2.74 | 1.87 | 0.54 | 1.26 | 1.64 | 2.18 |
| ROIC %i | 4.45 | 3.47 | 2.14 | 2.99 | 3.81 | 4.85 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 4.41 | 3.43 | 2.44 | 2.81 | 3.07 | 3.31 |
| FCF / sales %i | 2.32 | 5.01 | 3.35 | 3.28 | 4.40 | 2.46 |
| Current ratioi | 1.70 | 1.59 | 1.40 | 1.40 | 1.35 | 1.23 |
| Quick ratioi | 1.63 | 1.54 | 1.37 | 1.36 | 1.31 | 1.19 |
| Debt / assetsi | 33.90 | 31.03 | 48.60 | 48.59 | 45.16 | 42.92 |
| LT debt / equityi | 58.15 | 56.15 | 133.09 | 131.20 | 126.18 | 110.41 |
| Interest coveragei | 3.02 | 2.62 | 1.75 | 1.79 | 1.85 | 1.89 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Care Partners is the largest reported line at 95.92% of revenue, across 4 reported segments.
- The next-largest line, Care Enablement, is a distant second at 8.80% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Care Partners95.92%
Care Enablement8.80%
Care Delivery7.68%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.